COMPARATIVE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS

Abstract

Indirect comparisons of new oral anticoagulants are performed with focus on their safety. Apixaban, an oral inhibitor of Xa factor, nowadays can be considered as a drug with very good safety profile according to randomized trials results and performed indirect comparisons.

Keywords

• фибрилляция предсердий
• профилактика инсульта
• геморрагические осложнения
• апиксабан
• дабигатран
• ривароксабан